Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN10401455
ISRCTN10401455
Completed
未知

Establish and analyse the safety and efficacy of an integrated care model for the management of patients receiving oral anti-cancer agents in the community by an Advanced Nurse Practitioner (ANP): a pilot study

Irish Cancer Society0 sites37 target enrollmentNovember 30, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Irish Cancer Society
Enrollment
37
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

2022 Preprint results in https://doi.org/10.1101/2022.02.23.22271044 Results of phase I and protocol for phase II (added 23/09/2022) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36259243/ Qualitative study (added 20/10/2022) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38424625/ (added 01/03/2024)

Registry
who.int
Start Date
November 30, 2020
End Date
December 31, 2022
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Irish Cancer Society

Eligibility Criteria

Inclusion Criteria

  • •1\. Currently receiving an oral anti\-cancer treatment
  • •2\. Have received OAM within 6 months of data collection commencing
  • •3\. Aged 18 years and over
  • •4\. Cognitively able to provide informed consent and complete the study activities
  • •5\. An ECOG performance status of 0\-2

Exclusion Criteria

  • •1\. Refusal to participate
  • •2\. Patients not taking oral anticancer medication.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
A Phase I/II study evaluating the safety and activity of pegylated recombinant human arginase (BCT-100) in relapsed/refractory cancers of children and young adults
ISRCTN21727048niversity of Birmingham49
Active, not recruiting
Phase 1
A phase I/II study to determine efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteersCOVID-19 (SARS-CoV-2 infection)Infections and Infestations
ISRCTN15281137niversity of Oxford1,077
Recruiting
Phase 1
A Phase I/II study to assess the safety and efficacy of full-spectrum medicinal cannabis plant extract 0.08% THC (NTI164) in the treatment of Rett syndrome (RTT)Rett SyndromeNeurological - Neurodegenerative diseases
ACTRN12623000563662Fenix Innovation Group14
Not yet recruiting
Phase 1
CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut SyndromeLennox-Gastaut Syndrome (LGS)Dravet Syndrome (DS)
NCT06738732Alexander Rotenberg25
Active, not recruiting
Phase 1
Phase I/II Study of MK-3475 in Combination with Trametinib and Dabrafenibadvanced or metastatic melanoma - all parts of the trialadvanced (unresectable and/or metastatic) solid tumours - Parts 4 and 5MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-000681-55-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.190